guest ::
| Home > Publications database > Status epilepticus and benzodiazepine treatment: Use, underdosing and outcome - insights from a retrospective, multicentre registry > print |
| Home > Publications database > Status epilepticus and benzodiazepine treatment: Use, underdosing and outcome - insights from a retrospective, multicentre registry > print |
| 001 | 1007669 | ||
| 005 | 20231027114405.0 | ||
| 024 | 7 | _ | |a 10.1016/j.seizure.2023.03.020 |2 doi |
| 024 | 7 | _ | |a 1059-1311 |2 ISSN |
| 024 | 7 | _ | |a 1532-2688 |2 ISSN |
| 024 | 7 | _ | |a 2128/34461 |2 Handle |
| 024 | 7 | _ | |a 37004393 |2 pmid |
| 024 | 7 | _ | |a WOS:001031705300001 |2 WOS |
| 037 | _ | _ | |a FZJ-2023-02152 |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Kohle, Felix |0 P:(DE-HGF)0 |b 0 |e Corresponding author |
| 245 | _ | _ | |a Status epilepticus and benzodiazepine treatment: Use, underdosing and outcome - insights from a retrospective, multicentre registry |
| 260 | _ | _ | |a Oxford [u.a.] |c 2023 |b Elsevier |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1685006542_28121 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Objective: To explore the reasons for and outcomes of non- or undertreatment with benzodiazepines (BZDs) in status epilepticus (SE).Methods: We retrospectively analysed all SE patients from the urban area of Cologne over two years.Results: 328 SE patients were eligible, and only 72% were initially treated with BZDs. Of these, only 21.6% were treated sufficiently with BZDs according to current guidelines. SE patients not initially treated with BZDs were significantly older, had less often known epilepsy, had a prolonged arrival time to the emergency room, and presented more often with a non-generalised convulsive semiology. Regarding adequate dosages, patients with a generalised convulsive SE seemed to benefit from a sufficient BZD dosing with significantly shortened mean ventilation duration (37.1 to 208 h), decreased mean intensive care unit (1.7 to 5 days) and in-hospital stay (4.1 to 8.8 days). In contrary, aggressive BZD treatment in non-generalised convulsive SE resulted in a longer inpatient stay (9.2 to 5.8 days) and lower favourable outcome rates at discharge (16% to 63%).Conclusions: The current SE treatment guidelines for first-line BZD therapy in SE were violated in most patients. Sufficient BZD dosing was beneficial in generalised convulsive SE, but not in other forms of SE. SE semiology might be crucial for treatment decisions with BZDs. Further treatment evidence especially in non-generalised convulsive SE is urgently needed.Keywords: Anticonvulsants; Benzodiazepines; Critical care; Guideline adherence; Seizures. |
| 536 | _ | _ | |a 5251 - Multilevel Brain Organization and Variability (POF4-525) |0 G:(DE-HGF)POF4-5251 |c POF4-525 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de |
| 700 | 1 | _ | |a Madlener, Marie |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Bruno, Emanuel F. |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Fink, Gereon R. |0 P:(DE-Juel1)131720 |b 3 |u fzj |
| 700 | 1 | _ | |a Limmroth, Volker |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Burghaus, Lothar |0 P:(DE-HGF)0 |b 5 |
| 700 | 1 | _ | |a Malter, Michael P. |0 P:(DE-HGF)0 |b 6 |
| 773 | _ | _ | |a 10.1016/j.seizure.2023.03.020 |g Vol. 107, p. 114 - 120 |0 PERI:(DE-600)2002585-3 |p 114 - 120 |t Seizure |v 107 |y 2023 |x 1059-1311 |
| 856 | 4 | _ | |y Restricted |u https://juser.fz-juelich.de/record/1007669/files/Kohle_2023_European%20Journal%20of%20Epilepsy_Status%20epilepticus%20and%20benzodiazepine%20treatment.pdf |
| 856 | 4 | _ | |y OpenAccess |u https://juser.fz-juelich.de/record/1007669/files/Post%20print.pdf |
| 909 | C | O | |o oai:juser.fz-juelich.de:1007669 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 3 |6 P:(DE-Juel1)131720 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Natural, Artificial and Cognitive Information Processing |1 G:(DE-HGF)POF4-520 |0 G:(DE-HGF)POF4-525 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-500 |4 G:(DE-HGF)POF |v Decoding Brain Organization and Dysfunction |9 G:(DE-HGF)POF4-5251 |x 0 |
| 914 | 1 | _ | |y 2023 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2022-11-29 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2022-11-29 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2023-10-22 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-10-22 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b SEIZURE-EUR J EPILEP : 2022 |d 2023-10-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-22 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2023-10-22 |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-3-20090406 |k INM-3 |l Kognitive Neurowissenschaften |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-Juel1)INM-3-20090406 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|